. 2015 Jul 21;21(27):8271–8283. doi: 10.3748/wjg.v21.i27.8271

Table 4.

Pancreatic cancer studies n (%)

Author	Type of microsphere	Type of mets (patients)	Response criteria	Response	Median OS
(publish date and study type)	(average dosage or activity)	Type of mets (patients)	@ 1^st assessment	Response	Median OS
Michl et al[43]	SIR-Spheres	Pancreatic (19)	RECIST	9/13 (64.3) PR	9 mo
(12/2013, RS)	(1.0-2.5 Gbq)		@ 2.6 mo (median)	4/13 (35.7) PD
				6 lost
Cao et al[32]	SIR-Spheres	Pancreatic (7)	RECIST	2 (40) PR	No median OS
(11/2010, RS)	(no dosage info)		@ 1-2 mo	1 (20) SD	1 patient survived to 15 mo
				2 (40) PD
				2 lost
Pöpperl et al[45]	SIR-Spheres	Pancreatic (1, data extracted from larger study)	PET	1 (100) Regression	None
(4/2005, PC)	(mean 2.27 Gbq)	Pancreatic (1, data extracted from larger study)	@ 3 mo	1 (100) Regression	None

PC: Prospective cohort study; RS: Retrospective study; CR: Complete response; PR: Progressive response; PD: Progressive disease; SD: Stable disease; OS: Overall survival; OR: Overall response.